Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, New Engl J Med, 356, 115, 10.1056/NEJMoa065044 Motzer, 2019, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, Lancet Oncol, 20, 1370, 10.1016/S1470-2045(19)30413-9 Albiges, 2020, Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, Esmo Open, 5, 10.1136/esmoopen-2020-001079 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, New Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Powles, 2020, Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial, Lancet Oncol, 21, 1563, 10.1016/S1470-2045(20)30436-8 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, New Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Choueiri, 2020, Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, Ann Oncol, 31, 1030, 10.1016/j.annonc.2020.04.010 Choueiri, 2021, Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma, New Engl J Med, 384, 829, 10.1056/NEJMoa2026982 Motzer, 2021, Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma, New Engl J Med, 10.1056/NEJMoa2035716 Pennock, 2015, The evolving role of immune checkpoint inhibitors in cancer treatment, Oncol, 20, 812, 10.1634/theoncologist.2014-0422 Schmidt, 2019, Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer, Semin Immunopathol, 41, 21, 10.1007/s00281-018-0714-9 Hartmann, 2009, Tyrosine kinase inhibitors – A review on pharmacology, metabolism and side effects, Curr Drug Metab, 10, 470, 10.2174/138920009788897975 Rini, 2007, Vascular endothelial growth factor–targeted therapy in renal cell carcinoma: Current status and future directions, Clin Cancer Res, 13, 1098, 10.1158/1078-0432.CCR-06-1989 Martini, 2021, Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma, World J Urol, 1 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, J Clin Epidemiol, 62, 1006, 10.1016/j.jclinepi.2009.06.005 Armijo-Olivo, 2012, Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research, J Eval Clin Pract, 18, 12, 10.1111/j.1365-2753.2010.01516.x Zhang, 2020, Restricted mean survival time for interval-censored data, Stat Med, 39, 3879, 10.1002/sim.8699 Cox, 1972, Regression models and life-tables, J Royal Statistical Soc Ser B Methodol, 34, 187 Stewart, 2002, To IPD or not to IPD?, Eval Health Prof, 25, 76, 10.1177/0163278702025001006 Satagopan, 2017, Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale, Contemp Clin Trials, 63, 40, 10.1016/j.cct.2017.02.007 Guyot, 2012, Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves, Bmc Med Res Methodol, 12, 9, 10.1186/1471-2288-12-9 Grambsch, 1994, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81, 515, 10.1093/biomet/81.3.515 Klein, 2008, SAS and R functions to compute pseudo-values for censored data regression, Comput Meth Prog Bio, 89, 289, 10.1016/j.cmpb.2007.11.017